U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug

Source: 
Yahoo/Reuters
snippet: 

The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.

The FDA's decision will allow the drug, developed along with Sanofi SA, to be prescribed to reduce the overall risk of major adverse cardiovascular events (MACE).